<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04833855</url>
  </required_header>
  <id_info>
    <org_study_id>20190194</org_study_id>
    <nct_id>NCT04833855</nct_id>
  </id_info>
  <brief_title>Study to Evaluate Tezepelumab in Adults With Chronic Spontaneous Urticaria</brief_title>
  <acronym>INCEPTION</acronym>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-Ranging, Phase 2b Study to Evaluate Efficacy and Safety of Tezepelumab for the Treatment of Chronic Spontaneous Urticaria</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate the effect of tezepelumab on improvement&#xD;
      in the Urticaria Activity Score over 7 days (UAS7).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 15, 2021</start_date>
  <completion_date type="Anticipated">March 29, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 6, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline in Urticaria Activity Score over 7 days (UAS7)</measure>
    <time_frame>Baseline to Week 16</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with a Complete Response in Urticaria Activity Score over 7 Days (UAS7)</measure>
    <time_frame>Week 16</time_frame>
    <description>Complete response is defined as having a UAS7 score of 0 at week 16.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Itch Severity Score over 7 Days (ISS7)</measure>
    <time_frame>Baseline to Week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Hives Severity Score over 7 Days (HSS7)</measure>
    <time_frame>Baseline to Week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with a Urticaria Activity Score over 7 days (UAS7) Score of 6 or Below</measure>
    <time_frame>Week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with a Reduction from Baseline in Urticaria Activity Score over 7 days (UAS7) of 10 or More</measure>
    <time_frame>Baseline to Week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with a Complete Resolution of Itch using the Itch Severity Score over 7 Days (ISS7)</measure>
    <time_frame>Week 16</time_frame>
    <description>Complete resolution of itch is defined as having a ISS7 score of 0 at week 16.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with a Reduction from Baseline in Itch Severity Score over 7 days (ISS7) of 5 or More</measure>
    <time_frame>Baseline to Week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with a Complete Resolution of Hives using the Hives Severity Score over 7 Days (HSS7)</measure>
    <time_frame>Week 16</time_frame>
    <description>Complete resolution of hives is defined as a HSS7 score of 0 at week 16.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with a Reduction from Baseline in Hives Severity Score over 7 Days (HSS7) of 5.5 or More</measure>
    <time_frame>Baseline to Week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Sleep Interference Score</measure>
    <time_frame>Baseline to Week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Sleep Quality Diary Items</measure>
    <time_frame>Baseline to Week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Urticaria Control Test (UCT) Score</measure>
    <time_frame>Baseline to Week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Angioedema Activity Score over 7 Days (AAS7)</measure>
    <time_frame>Baseline to Week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Cumulative Weeks that Participants are Angioedema Occurrence-free using the Angioedema Activity Score over 7 Days (AAS7)</measure>
    <time_frame>Baseline to Week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Chronic Urticaria Quality of Life Questionnaire (CU-Q2oL) Score</measure>
    <time_frame>Baseline to Week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Dermatology Life Quality Index (DLQI) Score</measure>
    <time_frame>Baseline to Week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Angioedema Quality of Life Questionnaire (AE-QoL) Score</measure>
    <time_frame>Baseline to Week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Angioedema Control Test (AECT) Score</measure>
    <time_frame>Baseline to Week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Complete Control in Angioedema Control Test (AECT)</measure>
    <time_frame>Week 16</time_frame>
    <description>Complete control is defined as having an AECT score of 16 at week 16.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Work Productivity and Activity Impairment Questionnaire: Chronic Urticaria (WPAI-CU) Score</measure>
    <time_frame>Baseline to Week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Number of H1-antihistamine Rescue Medication Uses</measure>
    <time_frame>Baseline to Week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Concentration of Tezepelumab in Serum (Cmax)</measure>
    <time_frame>Baseline to Week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants who Experience an Adverse Event (AE)</measure>
    <time_frame>Baseline to Week 32</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants who Experience a Serious Adverse Event (SAE)</measure>
    <time_frame>Baseline to Week 32</time_frame>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Anticipated">270</enrollment>
  <condition>Chronic Spontaneous Urticaria</condition>
  <arm_group>
    <arm_group_label>Group 1: Omalizumab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants naive to anti-IgE therapies will receive omalizumab.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants naive to anti-IgE therapies will receive a placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3: Tezepelumab Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants naive to anti-IgE therapies will receive tezepelumab.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4: Tezepelumab Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants naive to anti-IgE therapies will receive tezepelumab.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 5: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants previously treated with anti-IgE therapies will receive a placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 6: Tezepelumab Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants previously treated with anti-IgE therapies will receive tezepelumab.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 7: Tezepelumab Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants previously treated with anti-IgE therapies will receive tezepelumab.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Tezepelumab Dose 1</intervention_name>
    <description>Subcutaneous injection.</description>
    <arm_group_label>Group 3: Tezepelumab Dose 1</arm_group_label>
    <arm_group_label>Group 6: Tezepelumab Dose 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Tezepelumab Dose 2</intervention_name>
    <description>Subcutaneous injection.</description>
    <arm_group_label>Group 4: Tezepelumab Dose 2</arm_group_label>
    <arm_group_label>Group 7: Tezepelumab Dose 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Omalizumab</intervention_name>
    <description>Subcutaneous injection.</description>
    <arm_group_label>Group 1: Omalizumab</arm_group_label>
    <other_name>Xolair</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Subcutaneous injection.</description>
    <arm_group_label>Group 2: Placebo</arm_group_label>
    <arm_group_label>Group 5: Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed informed consent must be obtained prior to participation in the study.&#xD;
&#xD;
          -  Male and female participants ≥ 18 years and ≤ 80 years of age at the time of&#xD;
             screening.&#xD;
&#xD;
          -  Chronic spontaneous urticaria (CSU) diagnosis for ≥ 6 months at the time of screening.&#xD;
&#xD;
          -  CSU inadequately controlled by second generation H1-antihistamines (sgAH) at&#xD;
             enrollment, as defined by all of the following:&#xD;
&#xD;
          -  The presence of itch and hives for &gt;= 6 consecutive weeks at any time prior to&#xD;
             screening visit 2&#xD;
&#xD;
          -  Failure to respond to an sgAH (up to 4 times the approved dose)&#xD;
&#xD;
          -  Urticaria Activity Score over 7 days (UAS7) (range 0-42) &gt;= 16 and Hives Severity&#xD;
             Score over 7 days (HSS7) (range 0-21) &gt;= 8 during the 7 days prior to enrollment&#xD;
&#xD;
          -  Participant with CSU who discontinued, is intolerant to, or was an inadequate&#xD;
             responder to anti-IgE therapies despite being treated with omalizumab 300 mg every 4&#xD;
             weeks (Q4W) for 6 months or higher doses of omalizumab &gt; 2 months or another anti-IgE&#xD;
             therapy. Note: This criterion is only applicable for anti-IgE-experienced&#xD;
             participants.&#xD;
&#xD;
          -  Participant willing and able to complete a daily symptom eDiary for the duration of&#xD;
             the study and adhere to the study visit schedules.&#xD;
&#xD;
          -  Subject must have been on a sgAH at approved or increased doses (up to 4x the approved&#xD;
             dose) for treatment of CSU for at least 3 consecutive days immediately prior to the&#xD;
             day -14 screening visit (screening visit 2) and must have documented current use on&#xD;
             the day of screening visit 1&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Disease related, including but not limited to:&#xD;
&#xD;
          -  Urticaria is solely due to inducible urticaria&#xD;
&#xD;
          -  Active dermatologic diseases (or conditions) other than chronic urticaria, with&#xD;
             urticaria wheals or angioedema symptoms such as urticarial vasculitis, erythema&#xD;
             multiforme, cutaneous mastocytosis (urticaria pigmentosa) and hereditary or acquired&#xD;
             angioedema (eg, due to C1 inhibitor deficiency)&#xD;
&#xD;
          -  Any other active skin disease associated with chronic itching that might influence, in&#xD;
             the investigator's opinion, the study evaluations and results (eg, atopic dermatitis,&#xD;
             dermatitis herpetiformis, senile pruritus, etc.)&#xD;
&#xD;
          -  History of a clinically significant infection within 28 days prior to day 1 that, in&#xD;
             the opinion of the investigator or medical monitor, might compromise the safety of the&#xD;
             participant in the study, interfere with evaluation of the investigational product, or&#xD;
             reduce the participants ability to participate in the study.&#xD;
&#xD;
          -  Evidence of active tuberculosis (TB) (in the opinion of the investigator), either&#xD;
             treated or untreated, or a positive purified protein derivative (PPD) or&#xD;
             QuantiFERON-TB Gold Plus (QFT-Plus) test for TB during screening.&#xD;
&#xD;
          -  History of malignancy, except for basal cell carcinoma or in situ carcinoma of the&#xD;
             cervix treated with apparent success with curative therapy ≥ 12 months prior to&#xD;
             screening or other malignancies treated with apparent success with curative therapy ≥&#xD;
             5 years prior to screening visit 1.&#xD;
&#xD;
          -  Subject is unable to complete an electronic patient diary or complete questionnaires,&#xD;
             or does not meet the required level of compliance with the eDiary during the 14 days&#xD;
             sgAH stabilization period&#xD;
&#xD;
        Other medical conditions&#xD;
&#xD;
          -  History or evidence of severe depression, schizophrenia, previous suicide attempts, or&#xD;
             suicidal ideation.&#xD;
&#xD;
        Prior/concomitant therapy, including but not limited to:&#xD;
&#xD;
          -  Treatment with any biologic products (eg, omalizumab, ligelizumab) within 4 months or&#xD;
             5 half-lives (whichever is longer) prior to screening visit 1&#xD;
&#xD;
          -  Routine (daily or every other day for 5 or more consecutive days) use of systemic&#xD;
             corticosteroids, systemic hydroxychloroquine, methotrexate, cyclosporine A,&#xD;
             cyclophosphamide, tacrolimus, azathioprine, and mycophenolate mofetil within 30 days&#xD;
             prior to screening visit 1.&#xD;
&#xD;
          -  Major surgery within 8 weeks prior to screening visit 1 or planned inpatient surgery&#xD;
             or hospitalization during the study period.&#xD;
&#xD;
          -  Receipt of Ig or blood products within 30 days prior to screening visit 1.&#xD;
&#xD;
          -  Vaccination with a live or attenuated vaccine within 30 days prior to screening visit&#xD;
             1. Receipt of inactive/killed vaccinations (eg, inactive influenza) is allowed,&#xD;
             provided the vaccinations are not administered within 7 days before or after any study&#xD;
             dosing visit.&#xD;
&#xD;
          -  Known hypersensitivity, including severe hypersensitivity reactions and/or history of&#xD;
             anaphylactic shock, to any of the products or components to be administered during&#xD;
             dosing or to products of similar chemical classes (ie, to murine, chimeric, or human&#xD;
             antibodies.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amgen Call Center</last_name>
    <phone>866-572-6436</phone>
    <email>medinfo@amgen.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Clinical Research Center of Alabama</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35209</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>First OC Dermatology</name>
      <address>
        <city>Fountain Valley</city>
        <state>California</state>
        <zip>92708</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Jonathan Corren MD Inc</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90025</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dermatology Research Associates</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Science Institute</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Asthma and Allergy Associates PC</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80907</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Community Research of South Florida</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dawes Fretzin Clinical Research Group, LLC</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46250</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Epiphany Dermatology of Kansas, LLC</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Family Allergy and Asthma Research Institute</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Asthma and Allergy Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>David Fivenson MD Professional Liability Company</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clarkston Skin Research</name>
      <address>
        <city>Clarkston</city>
        <state>Michigan</state>
        <zip>48346</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Henry Ford Medical Center - New Center One</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Bernstein Clinical Research Center LLC</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Aventiv Research Inc</name>
      <address>
        <city>Dublin</city>
        <state>Ohio</state>
        <zip>43016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Partners LLC</name>
      <address>
        <city>Johnston</city>
        <state>Rhode Island</state>
        <zip>02919</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Austin Institute for Clinical Research, Inc</name>
      <address>
        <city>Dripping Springs</city>
        <state>Texas</state>
        <zip>78620</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cutis Wellness Dermatology and Dermatopathology, PLLC</name>
      <address>
        <city>Laredo</city>
        <state>Texas</state>
        <zip>78041</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dermatology Research Institute Incorporated</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2J 7E1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Brunswick Dermatology Centre</name>
      <address>
        <city>Fredericton</city>
        <state>New Brunswick</state>
        <zip>E3B 1G9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>LEADER Research Inc.</name>
      <address>
        <city>Burlington</city>
        <state>Ontario</state>
        <zip>L7R 4H9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Lynderm Research Inc</name>
      <address>
        <city>Markham</city>
        <state>Ontario</state>
        <zip>L3P 1X3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cheema Research Incorporated</name>
      <address>
        <city>Mississauga</city>
        <state>Ontario</state>
        <zip>L5A 3V4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Dr. S. K. Siddha Medicine Professional Corporation</name>
      <address>
        <city>Newmarket</city>
        <state>Ontario</state>
        <zip>L3Y 5G8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Allergy Research Canada Incorporated</name>
      <address>
        <city>Niagara Falls</city>
        <state>Ontario</state>
        <zip>L2H 1H5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Gordon Sussman Clinical Research Incorporated</name>
      <address>
        <city>North York</city>
        <state>Ontario</state>
        <zip>M3B 3S6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinique Spécialisée en Allergie de la Capitale</name>
      <address>
        <city>Quebec</city>
        <zip>G1V 4W2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Brest - Hôpital Morvan</name>
      <address>
        <city>Brest</city>
        <zip>29200</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Charité Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Dresden</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin Mainz</name>
      <address>
        <city>Mainz</city>
        <zip>55101</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Laiko General Hospital of Athens</name>
      <address>
        <city>Athens</city>
        <zip>11527</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Attikon University General Hospital of Athens</name>
      <address>
        <city>Athens</city>
        <zip>12462</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Andreas Syggros Hospital</name>
      <address>
        <city>Athens</city>
        <zip>16121</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>George Papageorgiou General Hospital of Thessaloniki</name>
      <address>
        <city>Thessaloniki</city>
        <zip>56403</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico</name>
      <address>
        <city>Milano</city>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fondazione Policlinico Tor Vergata</name>
      <address>
        <city>Roma</city>
        <zip>00133</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Policlinico Universitario Agostino Gemelli</name>
      <address>
        <city>Roma</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>IRCCS Istituto Clinico Humanitas</name>
      <address>
        <city>Rozzano MI</city>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Citta della Salute e della Scienza di Torino</name>
      <address>
        <city>Torino</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fujita Health University Bantane Hospital</name>
      <address>
        <city>Nagoya-shi</city>
        <state>Aichi</state>
        <zip>454-8509</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hiroshima University Hospital</name>
      <address>
        <city>Hiroshima-shi</city>
        <state>Hiroshima</state>
        <zip>734-8551</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kosugi Dermatology Clinic</name>
      <address>
        <city>Kawasaki-shi</city>
        <state>Kanagawa</state>
        <zip>211-0063</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nomura Dermatology Clinic</name>
      <address>
        <city>Yokohama-shi</city>
        <state>Kanagawa</state>
        <zip>221-0825</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kume Clinic</name>
      <address>
        <city>Sakai-shi</city>
        <state>Osaka</state>
        <zip>593-8324</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nihon University Itabashi Hospital</name>
      <address>
        <city>Itabashi-ku</city>
        <state>Tokyo</state>
        <zip>173-8610</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>NTT Medical Center Tokyo</name>
      <address>
        <city>Shinagawa-ku</city>
        <state>Tokyo</state>
        <zip>141-8625</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hallym University Dongtan Sacred Heart Hospital</name>
      <address>
        <city>Hwaseong-si, Gyeonggi-do</city>
        <zip>18450</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam-si, Gyeonggi-do</city>
        <zip>13620</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Severance Hospital, Yonsei University Health System</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hallym University Kangnam Sacred Heart Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>07441</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ajou University Hospital</name>
      <address>
        <city>Suwon-si, Gyeonggi-do</city>
        <zip>16499</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Uniwersyteckie Centrum Kliniczne</name>
      <address>
        <city>Gdansk</city>
        <zip>80-214</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>SPZOZ Centralny Szpital Kliniczny Uniwersytetu Medycznego w Lodzi</name>
      <address>
        <city>Lodz</city>
        <zip>92-213</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Samodzielny Publiczny Szpital Kliniczny nr 1 w Lublinie</name>
      <address>
        <city>Lublin</city>
        <zip>20-081</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kliniczny Szpital Wojewodzki nr 1 im Fryderyka Chopina</name>
      <address>
        <city>Rzeszow</city>
        <zip>35-055</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Wojskowy Instytut Medyczny</name>
      <address>
        <city>Warszawa</city>
        <zip>04-141</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital del Mar</name>
      <address>
        <city>Barcelona</city>
        <state>Cataluña</state>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <state>Cataluña</state>
        <zip>08041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari de Bellvitge</name>
      <address>
        <city>Hospitalet de LLobregat</city>
        <state>Cataluña</state>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario de Valencia</name>
      <address>
        <city>Valencia</city>
        <state>Comunidad Valenciana</state>
        <zip>46014</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>April 5, 2021</study_first_submitted>
  <study_first_submitted_qc>April 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 6, 2021</study_first_posted>
  <last_update_submitted>November 10, 2021</last_update_submitted>
  <last_update_submitted_qc>November 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CSU</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urticaria</mesh_term>
    <mesh_term>Chronic Urticaria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Omalizumab</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.</ipd_time_frame>
    <ipd_access_criteria>Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.</ipd_access_criteria>
    <ipd_url>https://www.amgen.com/datasharing</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

